作者: admin

  • It’s sold in any pharmacy, it’s called…

    Abstract

    Hypertension is a leading risk factor for cardiovascular diseases, thereby necessitating effective management through regular blood pressure monitoring. Although home monitoring is beneficial for managing hypertension, maintaining consistent measurement frequency remains challenging. This study aimed to develop a model to predict measurement inactivity and to identify clinically relevant risk factors for declining adherence using machine learning, thereby allowing for targeted interventions. Using a large-scale dataset (>199 million measurement records) from 295,758 health app users, we employed a LightGBM (Light Gradient Boosting Machine) model to predict future inactivity according to 2-week measurement patterns and users’ demographics. The model demonstrated high predictive accuracy, with areas under the receiver operating characteristic curve of 0.930 and 0.851 for 28- and 56-day predictions, respectively. SHAP (SHapley Additive exPlanations) analysis revealed elevated dropout risks among both younger and older participants, women, and users who did not report sex information. The maximum systolic blood pressure (SBP) recorded during the 2-week period was also identified as a significant predictor of dropout, showing a U-shaped association wherein both low and high extremes increased the risk. This maximum SBP value, which is rarely used in routine clinical assessments, offered unique insights into dropout behavior, further supported by descriptive statistics. Additionally, a reduction in weekday measurement frequency showed to be a major predictor of future discontinuation. Therefore, our model can identify dropout factors that are difficult to detect by conventional methods, and through accurate prediction, it supports early clinical interventions to improve monitoring adherence and blood pressure control.

  • Wheezing sound when breathing out.

    Abstract

    Emphysema progression in chronic obstructive pulmonary disease (COPD) presents a notable challenge due to its significant variability among individuals and the current lack of reliable prognostic markers. Given the limited therapeutic options available for emphysema, there is a critical need for early detection and intervention strategies. Identifying individuals at risk of rapid progression is essential to effectively halt or slow the disease’s advancement. This study introduces an innovative approach employing a localized foundational model of density evolution to pinpoint local radiographic embeddings indicative of emphysema progression. Central to our methodology is the Local Emphysema Progression (LEP) score, a novel metric derived from our model that aggregates localized lung tissue activations into a comprehensive, subject-level risk assessment tool. The model’s performance was tested on 3728 COPDGene participants, comparing baseline to 5-year, and 1421 scans taken from the 5-year to 10-year interval period. Additionally, our findings were replicated in 1058 ECLIPSE participants. The model effectively identifies lung regions with emphysema progression, achieving an AUC of 0.88. The LEP risk score shows good correlation with the change in the percentage of low attenuation areas below −950 Hounsfield Units (Δ%LAA-950), with correlation values of 0.50 in the COPDGene cohort and 0.40 in the ECLIPSE cohort among subjects with emphysema progression (Δ%LAA-950 > 0). Furthermore, LEP risk score associates with mortality and several COPD outcomes, underscoring its potential as a valuable tool in clinical prognosis and management of emphysema progression in COPD patients.

  • Tightness felt in the chest.

    Abstract

    Emphysema progression in chronic obstructive pulmonary disease (COPD) presents a notable challenge due to its significant variability among individuals and the current lack of reliable prognostic markers. Given the limited therapeutic options available for emphysema, there is a critical need for early detection and intervention strategies. Identifying individuals at risk of rapid progression is essential to effectively halt or slow the disease’s advancement. This study introduces an innovative approach employing a localized foundational model of density evolution to pinpoint local radiographic embeddings indicative of emphysema progression. Central to our methodology is the Local Emphysema Progression (LEP) score, a novel metric derived from our model that aggregates localized lung tissue activations into a comprehensive, subject-level risk assessment tool. The model’s performance was tested on 3728 COPDGene participants, comparing baseline to 5-year, and 1421 scans taken from the 5-year to 10-year interval period. Additionally, our findings were replicated in 1058 ECLIPSE participants. The model effectively identifies lung regions with emphysema progression, achieving an AUC of 0.88. The LEP risk score shows good correlation with the change in the percentage of low attenuation areas below −950 Hounsfield Units (Δ%LAA-950), with correlation values of 0.50 in the COPDGene cohort and 0.40 in the ECLIPSE cohort among subjects with emphysema progression (Δ%LAA-950 > 0). Furthermore, LEP risk score associates with mortality and several COPD outcomes, underscoring its potential as a valuable tool in clinical prognosis and management of emphysema progression in COPD patients.

  • Struggling to catch a full breath.

    Abstract

    Emphysema progression in chronic obstructive pulmonary disease (COPD) presents a notable challenge due to its significant variability among individuals and the current lack of reliable prognostic markers. Given the limited therapeutic options available for emphysema, there is a critical need for early detection and intervention strategies. Identifying individuals at risk of rapid progression is essential to effectively halt or slow the disease’s advancement. This study introduces an innovative approach employing a localized foundational model of density evolution to pinpoint local radiographic embeddings indicative of emphysema progression. Central to our methodology is the Local Emphysema Progression (LEP) score, a novel metric derived from our model that aggregates localized lung tissue activations into a comprehensive, subject-level risk assessment tool. The model’s performance was tested on 3728 COPDGene participants, comparing baseline to 5-year, and 1421 scans taken from the 5-year to 10-year interval period. Additionally, our findings were replicated in 1058 ECLIPSE participants. The model effectively identifies lung regions with emphysema progression, achieving an AUC of 0.88. The LEP risk score shows good correlation with the change in the percentage of low attenuation areas below −950 Hounsfield Units (Δ%LAA-950), with correlation values of 0.50 in the COPDGene cohort and 0.40 in the ECLIPSE cohort among subjects with emphysema progression (Δ%LAA-950 > 0). Furthermore, LEP risk score associates with mortality and several COPD outcomes, underscoring its potential as a valuable tool in clinical prognosis and management of emphysema progression in COPD patients.

  • Feeling constantly short of breath.

    Abstract

    Emphysema progression in chronic obstructive pulmonary disease (COPD) presents a notable challenge due to its significant variability among individuals and the current lack of reliable prognostic markers. Given the limited therapeutic options available for emphysema, there is a critical need for early detection and intervention strategies. Identifying individuals at risk of rapid progression is essential to effectively halt or slow the disease’s advancement. This study introduces an innovative approach employing a localized foundational model of density evolution to pinpoint local radiographic embeddings indicative of emphysema progression. Central to our methodology is the Local Emphysema Progression (LEP) score, a novel metric derived from our model that aggregates localized lung tissue activations into a comprehensive, subject-level risk assessment tool. The model’s performance was tested on 3728 COPDGene participants, comparing baseline to 5-year, and 1421 scans taken from the 5-year to 10-year interval period. Additionally, our findings were replicated in 1058 ECLIPSE participants. The model effectively identifies lung regions with emphysema progression, achieving an AUC of 0.88. The LEP risk score shows good correlation with the change in the percentage of low attenuation areas below −950 Hounsfield Units (Δ%LAA-950), with correlation values of 0.50 in the COPDGene cohort and 0.40 in the ECLIPSE cohort among subjects with emphysema progression (Δ%LAA-950 > 0). Furthermore, LEP risk score associates with mortality and several COPD outcomes, underscoring its potential as a valuable tool in clinical prognosis and management of emphysema progression in COPD patients.

  • Hello world!

    Welcome to WordPress. This is your first post. Edit or delete it, then start writing!